BLOCker sequencing

Transgenomics' CEO said these first forays into next-gen sequencing don't represent a shift in the company's strategy, which has so far been focused on Sanger sequencing and PCR technologies for molecular diagnostics.

A Transgenomic official said the company has signed deals "for a number of significant high-value projects" with pharmaceutical firms, which promise to "swell the [segment to] $1.5 million or more in the second quarter, plus [bring in] significant revenues throughout the remainder of the year."

The new method, called BLOCker sequencing, uses blocking oligos to increase the sensitivity of Sanger sequencing for specific mutations, for example in tumors or viral populations.

Researchers find that historical factors influence which genes are the most highly studied, the Atlantic reports.

The US National Science Foundation's new sexual harassment policy is to go into effect next month, according to Nature News.

Researchers report using genotyping to tie together illegal ivory shipments and trace them back to a handful of cartels, the New York Times reports.

In Nature this week: genomic ancestry analysis of Sardinians, current noncoding mutations in colorectal cancer, and more.